House Receives Notices of DEA Proposals and Final Rules on Emerging Controlled Substances
WASHINGTON — The House recorded receipt of 18 Drug Enforcement Administration regulatory communications and referred them to the Energy and Commerce Committee on Oct. 22. The filings cover emerging controlled substances, precursor chemicals, sleep medicines and manufacturing quotas EXECUTIVE COMMUNICATIONS, ETC.House · 2026-10-22View source.
The House record says the communications were taken from the Speaker’s table and referred under House Rule XIV. That is a congressional processing step, not a House vote to approve the DEA actions and not a new statute.
The entries use different labels. A notice of proposed rulemaking is an agency proposal. A proposed amendment is also proposed action. A final rule or final amendment is labeled final in the communication. A temporary amendment is labeled temporary. The House entry does not provide the underlying notices’ publication dates, effective dates, or enough information to establish which actions are currently in force.
The proposed-rule filings include a proposal to place tianeptine in Schedule I; a proposal involving 3,4-MDP-2-P methyl glycidic acid, a List I chemical; a proposal to designate phenethyl halides as List I chemicals; a proposal to revise manufacturing and procurement quota applications; and a proposal to move the sleep drugs suvorexant, lemborexant and daridorexant from Schedule IV to Schedule V EXECUTIVE COMMUNICATIONS, ETC.House · 2026-10-22View source.
The filings labeled final include rules or amendments concerning hexahydrocannabinol; four substances — 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA and MMB-FUBICA; CUMYL-PEGACLONE; 2-fluorodeschloroketamine; P2P methyl glycidic acid; MDMB-4en-PINACA; and N-pyrrolidino metonitazene and N-pyrrolidino protonitazene EXECUTIVE COMMUNICATIONS, ETC.House · 2026-10-22View source.
Other entries concern proposed temporary placement of 7-hydroxymitragynine above a specified threshold; temporary and proposed amendments involving mitragynine pseudoindoxyl, MGM-15 and MGM-16; proposed temporary placement of four chlorphine-related substances; and proposed temporary placement of O-desmethyltramadol EXECUTIVE COMMUNICATIONS, ETC.House · 2026-10-22View source.
The Record contains no statements from DEA officials, public-health officials, clinicians, patient advocates, toxicology experts, businesses or consumers. It also does not give the evidence behind the actions or their practical effects. The underlying DEA notices would be needed to determine effective dates, the agency’s reasoning, any public comments and how the rules could affect medical use, chemical suppliers, manufacturers or consumers.